{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-050881","form_type":"8-K","ticker":null,"cik":"0000924717","company_name":"SURMODICS INC","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.511433+00:00","generated_at":"2026-06-03T03:47:27.769399+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Surmodics Q2 revenue $32M (+18% YoY), GAAP net income $0.2M; raises FY2024 guidance; launches two thrombectomy devices","bullets":["Total revenue $32.0M, up 18% YoY; GAAP net income $0.2M vs loss of $7.7M in prior-year period.","Medical Device product sales up 40% to $11.1M, driven by SurVeil DCB commercial shipments and Pounce sales.","Adjusted EBITDA $4.8M, improving from $(1.5M) in Q2 fiscal 2023.","FY2024 guidance raised: revenue now $122-$124M; GAAP diluted loss per share $(0.90)-$(0.70) vs prior $(1.40)-$(1.10).","Commercial launch of Pounce Venous and Pounce LP thrombectomy systems; cash and investments $40.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-050881","json":"https://secwatch.observer/filing/0000950170-24-050881.json","markdown":"https://secwatch.observer/filing/0000950170-24-050881.md","text":"https://secwatch.observer/filing/0000950170-24-050881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/924717/000095017024050881/0000950170-24-050881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/924717/000095017024050881/srdx-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:47:27.769399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64bd4fbaacb6a69e05e9ca7bdf3c0a5068517dcd","claim":"SURMODICS INC reported second quarter ended March 31, 2024 results: revenue $32.0 million, net income $0.2 million. Guidance raised.","evidence_excerpt":"today reported financial results for its second quarter ended March 31, 2024, and updated financial guidance for its fiscal year ending September 30, 2024. Second Quarter Fiscal 2024 Financial Summary • Total Revenue of $32.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/924717/000095017024050881/0000950170-24-050881-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended March 31, 2024"},{"label":"Revenue","value":"$32.0 million"},{"label":"Net income","value":"$0.2 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}